Program Description
It is estimated that prostate cancer accounted for more than 27,300 deaths in the United States during 2009, which makes this malignancy the second leading cause of cancer death among men. Most cases of prostate cancer are identified while the disease is still in the localized stage and is potentially curable with local radiotherapy or surgery; however, 5% of cases are identified at the advanced stage, which remains incurable despite recent advances in first- and second-line therapies. Patients with advanced disease are treated with surgery and/or hormonal therapy to deplete androgen levels in the body. While androgen deprivation can be very successful at slowing the progression of prostate cancer, eventually the cancer will become refractory to hormone therapy, necessitating the development of effective second-line treatments. Median survival in patients with castration-resistant prostate cancer (CRPC) can be extended to 18 months with first-line treatment using docetaxel-based chemotherapy. The recent development of new cancer vaccines, cell-based immunotherapies, and targeted agents for advanced prostate cancer could provide additional, more effective treatment options for this disease. This program will update healthcare professionals on the latest research regarding the safety and efficacy of these novel cancer immunotherapies and targeted agents for the treatment of CRPC and describe emerging data on treatment strategies for patients with advanced prostate cancer as presented at the American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium.
Hosted by
Lee Freedman, MD
Learning Objectives
Upon completion of this activity, participants will be able to:
1. Evaluate recent data from clinical trials investigating the use of cancer vaccines, cell-based
immunotherapies, and novel targeted agents for the treatment of patients with CRPC.
Target Audience
This activity is intended for medical oncologists, urologists, and other healthcare professionals interested in the treatment of patients with prostate cancer.
Faculty/Disclosures
Disclosure of Financial Relationships With Any Commercial Interest
Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of or responsibility for the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship, participants must be informed that no relevant financial relationship exists.
Disclosure of Potential Conflicts of Interest
The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. Identified conflicts of interest are thoroughly evaluated for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing participants with high-quality, unbiased, and state-of-the-art education.
The following faculty reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process:
Charles George Drake, MD, PhD
Consultant
Amplimmune, Inc.
Bristol-Myers Squibb Company
Dendreon Corporation
Receipt of Intellectual Property Rights
Amplimmune, Inc.
Royalty
Mederex, Inc.
Daniel P. Petrylak, MD
Consultant
AstraZeneca Pharmaceuticals LP
Bristol-Myers Squibb Company
Celgene Corporation
GPC Biotech AG
ImClone Systems Incorporated
Millennium Pharmaceuticals, Inc.
Grant/Research Support
Abbott Laboratories
Amgen Inc.
AstraZeneca Pharmaceuticals LP
Boehringer Ingelheim
Celgene Corporation
CuraGen Corporation
Dendreon Corporation
Eisai Inc.
GlaxoSmithKline
ImClone Systems Incorporated
Medivation, Inc.
Merck & Co., Inc.
Pfizer Inc.
Progenics Pharmaceuticals, Inc.
The Rogosin Institute
sanofi-aventis
Institutional Disclosure
The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants to the CBCE include the commercial supporter of this activity as well as the manufacturers of certain drugs and/or devices discussed in this activity.
Staff Disclosure
The CBCE staff have declared they have no financial relationships that require disclosure.
Accreditation
Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The CBCE designates this educational activity for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of .25 hour of Category 1 credit for completing this program.
Provider
Educational Inquiries
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com
Commercial Support
The CBCE gratefully acknowledges the educational grant provided by Dendreon Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the latest edition of the Physicians' Desk Reference.
Instruction for Participation
Method of Participation for ReachMD
This radio program will be made available on www.reachmd.com/cme and www.thecbce.com.
Method of Participation for iPhone® or iPod touch®
This activity can be accessed using an iPhone® or iPod touch® and will be a featured program on the CBCE Oncology CME app and ReachMD MedicalRadio app, which may be downloaded from the Apple® App Store.
ReachMD Online Credit Instructions
Successful completion of this activity includes the following:
- Complete the online posttest and score 70% or above.
- Complete the online Evaluation and Request for Credit Form.
- Print your online certificate.
ReachMD MedicalRadio App Credit Instructions
Successful completion of this activity includes the following:
- Complete the online posttest and score 70% or above.
- Complete the online Evaluation and Request for Credit Form.
- To print your online certificate, please visit www.reachmd.com and log into your account.
CBCE Oncology CME App Credit Instructions
Successful completion of this activity includes the following:
- Complete the online posttest and score 70% or above.
- Complete the online Evaluation and Request for Credit Form.
- Participants will receive their certificates via e-mail 4-6 weeks after submission of the online Evaluation and Request for Credit Form.
Legal Disclaimer
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or Dendreon Corporation. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this activity.